Combination anti-IgE and anti-IL5 therapies in patients with severe persistent asthma and allergic bronchopulmonary aspergillosis (ABPA)

Many patients with severe persistent asthma have evidence of both Th2 and eosinophilic inflammation. This is often seen in ABPA with IgE levels>1000 U/mL and peripheral eosinophil counts>500 cells/mL, however, can also be seen without aspergillus sensitization. The optimal approach to steroid-sparing biologic therapy in such patients is unclear, and many continue to have active disease after a single biologic therapy is initiated.

Source: Journal of Allergy and Clinical Immunology - February 1, 2018 Category: Allergy & Immunology Authors: Jay Patel, Andrew G. Ayars, Lahari Rampur, Stephen Bronson, Matthew C. Altman Source Type: research